US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at -0.11 against a street estimate of -0.06 — a miss of 83.3%.
Analysts rate Alvotech a buy (6 buy, 1 hold, 0 sell out of 7) with an average price target of $6.80.
| Document | Date |
|---|---|
| Current report (6-K) · Q4 2026 HEADLINE NUMBERS • On October 14, 2026, Alvotech announced the submission of a European regulatory application for AVT29. • AVT29 is a proposed bios | 2026-10-14 |
| Current report (6-K) · Q4 2026 HEADLINE NUMBERS • On October 6, 2026, Alvotech announced a long-term strategic manufacturing partnership with LOTTE Biologics. • The filing provide | 2026-10-07 |
| Current report (6-K) · Q4 2026 HEADLINE NUMBERS • On October 5, 2026, the U.S. Food and Drug Administration (FDA) approved additional manufacturing capacity at Alvotech’s Reykjavik | 2026-10-05 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • On August 31, 2026, the FDA accepted Alvotech’s Biologics License Application (BLA) for AVT80 for review. • AVT80 is a proposed | 2026-08-31 |
| Current report (6-K) · Q3 2026 BUSINESS & SEGMENT HIGHLIGHTS • Alvotech announced an agreement with Lotus Pharmaceutical covering proposed biosimilars to durvalumab and emicizumab. | 2026-08-21 |
| Quarterly results (6-K) · Q2 2026 HEADLINE NUMBERS • Revenue was $211.6 million for the six months ended 30 June 2026, down from $306.0 million in the same period of 2025. • Product | 2026-08-19 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • On July 29, 2026, the U.S. Food and Drug Administration (FDA) closed its inspection of Alvotech’s manufacturing site. • The site | 2026-07-29 |
| Annual report FY2025 (20-F) HEADLINE NUMBERS • Fiscal year ended 31 December 2025. • Reported net profit of $27.9 million for 2025, compared with net losses of $231.9 million i | 2026-03-31 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Alvotech — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.